• Dowling & Partners


    Comprised of 15 analysts, our Equity Research team is in constant contact with management of both public and private companies to keep our clients abreast of industry trends and new developments. Our boutique model of “all insurance, all the time” allows our dedicated five person sales team to respond to our client’s needs quickly and provide timely access to senior research analysts. 


    Group Insurance and Employee Benefits Review

    Within the US Life Ins Industry, we continue to favor Group Ins & Employee Benefits business given the attractive risk/return profile & strong cash flow generation.  Additionally, favorable secular trends will support stronger top-line growth prospects for Group Ins & Employee Benefits providers.  1) the tight employement market & the robust business senitment will drive higher wages & more employee benefits.  2) the shift of employee benefits towards a defined contribution model will lead to a growing demand for supplemental & voluntary benefit products.  We argue the companies best positioned are those that focus on small mid case market and/or supplemental & voluntary benefits.  See our full Group Insurance & Employee Benefits Review


    2017 P/C U.S. Industry Reserves Continue to Erode Toward/Into Deficiency 

    Industry loss reserves appeared noticeably weaker in our analysis of the 2017 Schedule P, continuing the trends observed in last year's analysis, but with further erosion in the major long tail lines = a continuation of the "cheating phase".  By line trends were mixed and the major lines remain "out of phase".  Overall, the US reserves look about adequate but weaker than last year, with an increased likelihood of ultimately proving deficient.  See IBNR #11, 2018.  



    Q1:18 MI Review: Price Competition Dominates Q1 Discussions; No Change to Neutral Ratings

    As proved with the evolution to risk-based rate cards, this next step evolution in MI pricing could prove a neutral to positive as well.  The industry is cutting rates, but targeted returns do look to still be in the mid-teens.  The premium stock valuations for lower effective tax rates are also gone.   Over the nearer-term, we continue to believe that the rate actions/evolution need to prove out more, and we are still waiting on PMIERs 2.0 details. Given these considerations, we believe out Neutral ratings remain appropriate.  See our full review